Navigation Links
How Much Fish to Eat While Pregnant?
Date:4/11/2009

Experts debate pros, cons of consumption and mercury exposure

SATURDAY, April 11 (HealthDay News) -- Women who are pregnant should include fish in their diet for optimal maternal health and fetal growth and development. That much health experts agree on.

But just how much seafood moms-to-be can safely consume without exposing their unborn babies to dangerous levels of mercury is a matter of ongoing debate.

The U.S. Food and Drug Administration advises women to eat no more than 12 ounces a week, but a coalition of scientists in nutrition and medicine insists that expectant moms need at least that much.

"Recent data shows us that women are still not eating enough fish, and that's really alarming," said Judy Meehan, executive director of the National Healthy Mothers, Healthy Babies Coalition, an organization dedicated to disseminating the latest science on maternal and child health.

"There's simply no other way to get the omega-3s for brain development that you can from fish," she said.

Fish is packed with omega-3 fatty acids, a beneficial type of fat that is considered important for neural development.

Limiting fish intake to the government-recommended level, in fact, could be "detrimental" to a child's mental development, British and American researchers reported in 2007 in The Lancet. Their study found that children whose mothers ate at least three servings of fish a week during pregnancy performed better on tests of mental function.

In another study, Dr. Emily Oken, an assistant professor in the Department of Ambulatory Care and Prevention at Harvard Medical School and Harvard Pilgrim Health Care in Boston, examined the balance between the nutritional benefit and contaminant risk of consuming fish during pregnancy.

She and her colleagues asked 341 women about their fish consumption during the second trimester of pregnancy and tested the
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Leveraging Cloud Computing is the Latest Offering by ICG Consulting to Streamline Costs While Delivering Robust Business Process Solutions
2. New P.E. Drug Approved In Europe While Premature Ejaculation Cure Remains Out of Reach to American Men
3. Male Cosmetic Surgery Slows Down While Female Cosmetic Surgery Advances
4. Number of Revascularization Procedures, Related In-Hospital Mortality and Some Complications Decline, While Rates of Infection and Acute Respiratory Distress Syndrome (ARDS) Following Coronary Artery Bypass Graft (CABG) Surgery Increase
5. Saving Money While Protecting Your Health in Tough Economic Times
6. Patients, Senate, House Members Identify Significant Medicare Savings While Increasing Quality of Patient Care
7. Cell phone studies: While walking or driving, cell phones increase traffic, pedestrian fatalities
8. Please Dont Forget Me: Stories of the Survivors: New Spiritual Memoir Shares One Couples Reliance on God While Facing Adversity
9. Head Injury While Young Ups Epilepsy Risk
10. Americans Forfeit Healthy Habits While Traveling According to New Years Survey by Cambria Suites
11. The New Crystalens HD Gives Many Baby Boomers and Seniors an Opportunity to See Clearly at All Distances while Reducing or Eliminating the Need for Glasses
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
How Much Fish to Eat While Pregnant? 
How Much Fish to Eat While Pregnant?
Breaking Medicine Technology:Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Exploring standards to advance microbial genomics 9201 1Exploring standards to advance microbial genomics 9201 2Exploring standards to advance microbial genomics 9201 3Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 1Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 2Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 3Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 1Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 2Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 3
Other Medicine Technology:Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 2Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 3Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 4Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 6Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 7Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 8Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8